Pieris Pharmaceuticals (PIRS) News Today $16.01 +0.42 (+2.69%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSNovember 20 at 5:29 PM | businesswire.comPieris Pharmaceuticals (NASDAQ:PIRS) Rating Increased to Hold at StockNews.comNovember 20 at 3:49 AM | americanbankingnews.comPieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trialNovember 7, 2024 | markets.businessinsider.comAridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comPalvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual ConferenceOctober 15, 2024 | globenewswire.comPalvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic MalformationsOctober 3, 2024 | globenewswire.comKubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc.September 24, 2024 | barrons.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, ENV, AFBI on Behalf of ShareholdersAugust 16, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRSAugust 16, 2024 | prnewswire.comInside the deal: How Palvella Therapeutics plans to go public through a reverse merger with a Boston pharma firmAugust 16, 2024 | bizjournals.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersAugust 16, 2024 | globenewswire.comPIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q2 2024August 15, 2024 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersAugust 14, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRSAugust 13, 2024 | globenewswire.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 SharesAugust 13, 2024 | insidertrades.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of ShareholdersJuly 25, 2024 | stockhouse.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.July 24, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersJuly 24, 2024 | prnewswire.comWhy Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?July 24, 2024 | investorplace.comTraders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity FuturesJuly 24, 2024 | msn.comPieris Pharma Shares Double on Buyout Offer From Palvella TherapeuticsJuly 24, 2024 | marketwatch.comPieris Pharma surges on all-stock merger dealJuly 24, 2024 | msn.comPieris Pharmaceuticals, Inc.: Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger AgreementJuly 24, 2024 | finanznachrichten.dePIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024May 17, 2024 | investorplace.comPieris Pharmaceuticals: Q1 Earnings SnapshotMay 15, 2024 | washingtonpost.comPieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00April 24, 2024 | marketbeat.comPieris Pharmaceuticals (NASDAQ:PIRS) Sees Large Volume IncreasePieris Pharmaceuticals (NASDAQ:PIRS) Sees Unusually-High Trading VolumeApril 23, 2024 | marketbeat.comTrading was temporarily halted for "PIRS" at 07:04 PM with a stated reason of "News pending."April 23, 2024 | marketbeat.comAvalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72MApril 1, 2024 | msn.comPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 28, 2024 | finanznachrichten.dePieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 27, 2024 | finance.yahoo.comPIRS Apr 2024 2.500 callMarch 19, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc (PIRS)February 10, 2024 | investing.comPieris Pharmaceuticals, Inc. (PIRS)February 1, 2024 | finance.yahoo.comInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%December 18, 2023 | finance.yahoo.comPieris Pharmaceuticals Inc (PIRS) Earnings Dates & ReportsNovember 20, 2023 | investing.comPieris Pharmaceuticals Inc PIRSNovember 4, 2023 | morningstar.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's WhySeptember 25, 2023 | finance.yahoo.comIs Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisAugust 24, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowAugust 23, 2023 | finance.yahoo.comPieris (PIRS) Up On Receiving Milestone Payment From PartnerAugust 18, 2023 | msn.comPieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificAugust 17, 2023 | finance.yahoo.comPieris (PIRS) Pursues Strategic Alternatives, Stock RisesJuly 19, 2023 | finance.yahoo.comPieris Pharma Cuts Around 70% Workforce; Plans Strategic OptionsJuly 19, 2023 | markets.businessinsider.comPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 18, 2023 | finanznachrichten.deWhy Pieris Pharmaceuticals Shares Shooting Higher Today?July 18, 2023 | finance.yahoo.comPieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 18, 2023 | finance.yahoo.comTrading was temporarily halted for "PIRS" at 09:07 AM with a stated reason of "News pending."July 18, 2023 | marketbeat.comPieris Pharmaceuticals (NASDAQ: PIRS)July 13, 2023 | fool.com Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin PIRS Media Mentions By Week PIRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PIRS News Sentiment▼0.210.46▲Average Medical News Sentiment PIRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PIRS Articles This Week▼20▲PIRS Articles Average Week Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FibroGen News PMV Pharmaceuticals News Oncolytics Biotech News Ikena Oncology News Chimerix News PDS Biotechnology News Clearside Biomedical News Quince Therapeutics News I-Mab News ESSA Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PIRS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PIRS Stock Alerts